Reactions 1680, p100 - 2 Dec 2017 ALK G1269A mutation leading to crizotinib resistance: case report In a retrospective study of 8 patients, a 29-year-old man developed drug resistance due to ALK G1269A mutation during treatment with crizotinib [route, dosages not stated]. He had a diagnosis of stage IV non-small-cell lung cancer (NSCLC) and he received anaplastic lymphoma kinase (ALK) inhibitor therapy. Initially, he received crizotinib therapy, which was followed by ceritinib therapy. During the crizotinib therapy, he developed ALK G1269A mutation, which led to the resistance of ALK inhibitor therapy [duration of treatment to reaction onset not stated]. On the ceritinib therapy, he had a remission of only 3 months. After this, his disease progressed with the pleural effusion and mediastinal lymph nodes development [reaction outcome not stated]. Author comment: "One patient, who experienced PD during alectinib treatment, had ALK G1269A mutation (patient 4). The G1269A mutation is reported to confer resistance to crizotinib while conferring sensitivity to alectinib and ceritinib; in this case, treatment with crizotinib before ceritinib treatment might affect G1269A mutation expression." Oya Y, et al. Clinical efficacy of alectinib in patients with ALK-rearranged non- small cell lung cancer after ceritinib failure. Anticancer Research 37: 6477-6480, No. 11, Nov 2017. Available from: URL: http://doi.org/10.21873/anticanres.12103 - Japan 803284654 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera